Ramon A C van Huet1, Nathalie M Bax1, Sarah C Westeneng-Van Haaften1, Muhamad Muhamad1, Marijke N Zonneveld-Vrieling2, Lies H Hoefsloot2, Frans P M Cremers3, Camiel J F Boon4, B Jeroen Klevering1, Carel B Hoyng1. 1. Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands Nijmegen Center of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
PURPOSE: To provide a clinical and genetic description of a patient cohort with Stargardt disease (STGD1) with identifiable foveal sparing. METHODS: Patients with retinal atrophy (defined as an absence of autofluorescence) that surrounded the fovea by at least 180° and did not include the fovea were defined as having foveal sparing; eyes with visual acuity (VA) worse than 20/200 were excluded. We reviewed the medical files and extracted data regarding medical history, VA, ophthalmoscopy, static perimetry, fundus photography, spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), fundus autofluorescence (FAF), and electroretinography (ERG). We screened each patient's ABCA4 gene for mutations. RESULTS: Seventeen eyes with foveal sparing were identified in 13 unrelated patients. In 4 eyes, the fovea gradually became atrophic after the initial foveal sparing. The mean age at onset was 51 years (range, 32-67 years). Visual acuity was 20/40 or better in all foveal sparing eyes and was 20/25 or better in 41%. Fundus autofluorescence imaging revealed hyperautofluorescent flecks and parafoveal retinal atrophy; SD-OCT revealed sharply delineated atrophy; and perimetry revealed parafoveal scotomas with intact foveal sensitivity. Finally, genetic screening identified mutations in 19 of the 26 ABCA4 gene alleles. CONCLUSIONS: Foveal sparing occurs mainly in patients with late-onset STGD1 and represents the milder end of the clinical spectrum in STGD1. The anatomy, metabolism, and biochemistry of the retina, as well as genetic variations in genes other than ABCA4, can influence the etiology of foveal sparing. Identifying these fovea-protecting factors will facilitate the future development of strategies designed to treat STGD1. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To provide a clinical and genetic description of a patient cohort with Stargardt disease (STGD1) with identifiable foveal sparing. METHODS:Patients with retinal atrophy (defined as an absence of autofluorescence) that surrounded the fovea by at least 180° and did not include the fovea were defined as having foveal sparing; eyes with visual acuity (VA) worse than 20/200 were excluded. We reviewed the medical files and extracted data regarding medical history, VA, ophthalmoscopy, static perimetry, fundus photography, spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), fundus autofluorescence (FAF), and electroretinography (ERG). We screened each patient's ABCA4 gene for mutations. RESULTS: Seventeen eyes with foveal sparing were identified in 13 unrelated patients. In 4 eyes, the fovea gradually became atrophic after the initial foveal sparing. The mean age at onset was 51 years (range, 32-67 years). Visual acuity was 20/40 or better in all foveal sparing eyes and was 20/25 or better in 41%. Fundus autofluorescence imaging revealed hyperautofluorescent flecks and parafoveal retinal atrophy; SD-OCT revealed sharply delineated atrophy; and perimetry revealed parafoveal scotomas with intact foveal sensitivity. Finally, genetic screening identified mutations in 19 of the 26 ABCA4 gene alleles. CONCLUSIONS: Foveal sparing occurs mainly in patients with late-onset STGD1 and represents the milder end of the clinical spectrum in STGD1. The anatomy, metabolism, and biochemistry of the retina, as well as genetic variations in genes other than ABCA4, can influence the etiology of foveal sparing. Identifying these fovea-protecting factors will facilitate the future development of strategies designed to treat STGD1. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Pablo Altschwager; Lucia Ambrosio; Emily A Swanson; Anne Moskowitz; Anne B Fulton Journal: Semin Pediatr Neurol Date: 2017-05-23 Impact factor: 1.636
Authors: Maria Fernanda Abalem; Benjamin Otte; Chris Andrews; Katherine A Joltikov; Kari Branham; Abigail T Fahim; Dana Schlegel; Cynthia X Qian; John R Heckenlively; Thiran Jayasundera Journal: Am J Ophthalmol Date: 2017-10-14 Impact factor: 5.258
Authors: Tjaša Krašovec; Marija Volk; Maja Šuštar Habjan; Marko Hawlina; Nataša Vidović Valentinčič; Ana Fakin Journal: Int J Mol Sci Date: 2022-07-02 Impact factor: 6.208
Authors: Xiangrong Kong; Kaoru Fujinami; Rupert W Strauss; Beatriz Munoz; Sheila K West; Artur V Cideciyan; Michel Michaelides; Mohamed Ahmed; Ann-Margret Ervin; Etienne Schönbach; Janet K Cheetham; Hendrik P N Scholl Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Frederick T Collison; Winston Lee; Gerald A Fishman; Jason C Park; Jana Zernant; J Jason McAnany; Rando Allikmets Journal: Retina Date: 2019-12 Impact factor: 4.256
Authors: Marcela D Mena; Angélica A Moresco; Sofía H Vidal; Diana Aguilar-Cortes; María G Obregon; Adriana C Fandiño; Juan M Sendoya; Andrea S Llera; Osvaldo L Podhajcer Journal: Front Genet Date: 2021-03-26 Impact factor: 4.599